Trulicity Cost in North Carolina 2026: Cash Price, Insurance, Medicaid & Compounding

What Is the Cash Price of Trulicity in North Carolina in 2026?

The manufacturer list price set by Eli Lilly is $931 per month for a four-pen carton of Trulicity, and cash-pay prices at North Carolina retail pharmacies in 2026 track almost exactly to that list price. Chains including CVS, Walgreens, Walmart, and Harris Teeter do not discount GLP-1 agonists meaningfully at the counter without a coupon or savings program.

Because pharmacy benefit managers (PBMs) negotiate rebates that rarely reach uninsured patients, you will pay close to the same $931 whether you walk into a Raleigh CVS or a Wilmington independent pharmacy. A 2023 analysis in JAMA found that net manufacturer prices for GLP-1 receptor agonists remained well above $700 per month even after rebate adjustments, leaving uninsured patients with effectively no relief at the register [1].

GoodRx and similar coupon platforms may show prices ranging from $870 to $940 at NC pharmacies, a modest 1 to 5% reduction that does not meaningfully change affordability. SingleCare coupons function similarly. Neither replaces manufacturer assistance programs for patients who qualify.

Splitting doses is not clinically recommended. Dulaglutide pens are prefilled single-dose devices; the drug cannot be transferred to a vial and divided. Each pen delivers exactly one weekly dose [2].

One practical approach: if your prescriber writes for the 0.75 mg starting dose rather than 1.5 mg, the carton price is identical because the pen count per carton is the same, so dose titration does not reduce cost.

Does North Carolina Medicaid Cover Trulicity?

North Carolina Medicaid does not cover Trulicity for type 2 diabetes as of January 2026. The NC Medicaid Drug Formulary places dulaglutide in a non-preferred or excluded tier for standard T2D management, meaning prior authorization will be denied for the majority of Medicaid beneficiaries seeking it for blood glucose control alone.

This contrasts with several other states where Medicaid programs added GLP-1 agents after cardiovascular outcome data emerged from the REWIND trial [3]. In REWIND (N=9,901), dulaglutide 1.5 mg reduced the composite of major adverse cardiovascular events by 12% vs. placebo (HR 0.88 to 95% CI 0.79, 0.99, P=0.026) over a median follow-up of 5.4 years [3]. Despite that outcome signal, NC Medicaid's preferred drug list has not expanded to include dulaglutide for routine T2D as a covered benefit.

NC Medicaid does cover metformin, sulfonylureas, and certain SGLT-2 inhibitors under preferred status. Patients who need a GLP-1 and cannot afford Trulicity out-of-pocket may qualify for Liraglutide (Victoza) under some formulary exceptions, but coverage decisions change quarterly. Check the current NC Medicaid formulary at NCTracks before assuming any status.

For patients with a documented cardiovascular indication, a prior authorization appeal citing the REWIND outcome data and the American Diabetes Association's 2024 Standards of Care recommendation for GLP-1 agonists in patients with established ASCVD may succeed in roughly 20 to 30% of cases based on national PA overturn data, though NC-specific rates are not publicly reported [4].

Which Commercial Insurance Plans Cover Trulicity in North Carolina?

Coverage varies by plan tier, but most major commercial payers operating in North Carolina include Trulicity on their formularies, typically at Tier 3 (preferred brand) or Tier 4 (non-preferred brand).

Blue Cross Blue Shield of NC lists dulaglutide as a Tier 3 non-preferred brand on most ACA marketplace and employer plans, with a typical copay of $60, $120 per month before deductible. After deductible is met, the copay usually drops to that tier rate.

Aetna and UnitedHealthcare plans sold through NC employers generally cover Trulicity at Tier 3 with step-therapy requirements. Step therapy means you must document a 90-day trial of metformin and one other agent (often a sulfonylurea or SGLT-2 inhibitor) before Trulicity is approved. Failing step therapy in writing before requesting Trulicity dramatically speeds up the prior authorization timeline.

Medicare Part D in North Carolina covers dulaglutide, but only for type 2 diabetes. Weight management is excluded under current Part D rules. The Inflation Reduction Act cap of $2,000 per year on out-of-pocket drug spending takes full effect in 2025 and continues into 2026, which meaningfully limits catastrophic cost exposure for Medicare patients on Trulicity [5].

The American Diabetes Association's 2024 Standards of Medical Care state: "For patients with type 2 diabetes and established cardiovascular disease, heart failure, or chronic kidney disease, a GLP-1 receptor agonist with proven cardiovascular benefit should be used" [4]. That language gives prescribers a strong clinical justification to attach to prior authorization appeals.

How Does the Eli Lilly Savings Card Work in North Carolina?

Eli Lilly's Trulicity savings card, administered through the Lilly Cares and Lilly Insulin Value Program infrastructure, reduces the monthly copay to as low as $25, $35 for eligible commercially insured patients. The card does not apply to Medicare, Medicaid, or any other federally funded insurance.

To use it, you register at LillyDirect.com or through your prescriber's office. The card is processed at the pharmacy counter like a secondary insurance. The pharmacy bills your primary insurance first, then applies the savings card to the remaining copay. Patients with high-deductible health plans benefit most during the pre-deductible phase, when the card can offset hundreds of dollars per month.

Income restrictions do not apply to the savings card itself. However, patients without insurance are not eligible. Uninsured patients must use a separate program, the Lilly Insulin Value Program or the Lilly Cares Foundation patient assistance program, which provides Trulicity at no cost to patients below 400% of the federal poverty level [6].

Application for the Lilly Cares Foundation program requires proof of income, proof of NC residency, and a completed prescription. Processing takes 2 to 4 weeks. Patients in financial hardship can also call 1-800-545-5979 for expedited bridge supply while the full application is reviewed.

Is Compounded Dulaglutide Legal in North Carolina?

Compounded dulaglutide is legal in North Carolina when prepared by a licensed 503A compounding pharmacy and dispensed pursuant to a valid patient-specific prescription, provided the FDA has designated dulaglutide (or the branded product Trulicity) as in shortage or when other regulatory conditions allowing compounding are met.

503A pharmacies are traditional compounding pharmacies regulated primarily by state boards of pharmacy. North Carolina's Board of Pharmacy oversees these facilities. They may compound dulaglutide for individual patients if a licensed prescriber has issued a valid prescription and the pharmacy is not operating as an outsourcing facility (503B), which faces additional federal oversight.

The FDA placed semaglutide on its drug shortage list in 2022, opening the door for widespread GLP-1 compounding. Dulaglutide's shortage status has been more variable. As of early 2026, some 503A pharmacies in North Carolina continue to compound dulaglutide citing intermittent supply constraints, but patients and prescribers should verify the current shortage designation at the FDA's drug shortage database before proceeding [7].

The North Carolina Medical Board has issued no specific prohibition on prescribing compounded GLP-1 agonists, but it does require that prescribers conduct appropriate clinical evaluation before writing any compounded drug prescription.

Compounded dulaglutide is not FDA-approved. Potency, sterility, and bioequivalence are not guaranteed to the same standard as the branded product. Patients switching from Trulicity to a compounded version should monitor blood glucose more closely during the transition period, particularly during the first four weeks.

The HealthRX clinical team uses a three-question access framework for North Carolina patients considering compounded dulaglutide:

1. Is the FDA shortage designation current and documented at the time of prescribing?
2. Has the 503A pharmacy passed a recent NC Board of Pharmacy inspection with no critical violations?
3. Does the patient have a documented contraindication to brand Trulicity (insurance exclusion, cost-related non-adherence) that justifies compounding over therapeutic substitution with a formulary-covered GLP-1?

Only when all three answers are yes does the HealthRX clinical team consider compounded dulaglutide appropriate for North Carolina patients. This approach mirrors guidance from the Alliance for Pharmacy Compounding's position statement on GLP-1 compounding published in 2023.

Can I Get Trulicity Through Telehealth in North Carolina?

Telehealth prescribing of Trulicity is legal in North Carolina. The state permits controlled and non-controlled prescription-only drugs to be prescribed via synchronous audio-video telehealth visits, provided the prescriber holds a valid NC medical license or qualifies under interstate compact provisions.

North Carolina joined the Interstate Medical Licensure Compact, which allows physicians licensed in compact member states to obtain an expedited NC license. Nurse practitioners and physician assistants operating via telehealth in NC must have a collaborative practice agreement with a supervising physician unless they hold independent practice authority.

The DEA's special telemedicine registration rule, finalized in late 2023, does not affect dulaglutide because dulaglutide is not a controlled substance. A prescriber can conduct an initial telehealth evaluation and write a Trulicity prescription in the same visit, without any prior in-person requirement [8].

HealthRX telehealth visits for Trulicity in North Carolina typically cover: medical history review, A1c and fasting glucose results, weight and BMI documentation, contraindication screening (personal or family history of medullary thyroid carcinoma or MEN2), and prior authorization initiation if the patient has commercial insurance.

The visit itself takes 20 to 30 minutes. Prescriptions are sent electronically to the patient's preferred pharmacy, which may be a retail NC pharmacy, a mail-order pharmacy, or a licensed 503A compounding pharmacy if a compounded product is clinically appropriate.

What Clinical Evidence Supports Using Trulicity?

Dulaglutide's efficacy and safety rest on a substantial body of trial data. The AWARD trial program (AWARD-1 through AWARD-8) established dose-dependent A1c reductions of 1.1% to 1.6% from baseline in patients with type 2 diabetes across a range of background therapies [9].

The REWIND cardiovascular outcome trial (N=9,901) is the most consequential study for patients with established or high-risk cardiovascular disease. Over 5.4 years of follow-up, patients randomized to dulaglutide 1.5 mg weekly experienced 12% fewer major adverse cardiovascular events (MACE) compared to placebo (HR 0.88 to 95% CI 0.79, 0.99, P=0.026) [3]. 69% of REWIND participants had no prior cardiovascular event at enrollment, a broader population than most other GLP-1 CV outcome trials.

Weight loss with dulaglutide is clinically meaningful but more modest than with higher-dose semaglutide. In the AWARD-11 trial (N=1,842), the 4.5 mg dulaglutide dose produced a mean A1c reduction of 2.02% and body weight reduction of 4.7 kg at 36 weeks, compared to 1.5 mg producing 1.54% A1c reduction and 2.7 kg weight loss [10].

The FDA label for Trulicity carries a boxed warning for thyroid C-cell tumors based on rodent data. Dulaglutide is contraindicated in patients with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 [2]. Common adverse effects include nausea (12 to 21% of patients), diarrhea (8 to 12%), vomiting (6 to 9%), and abdominal pain, generally most intense during the first 4 to 8 weeks and dose-titration periods.

Pancreatitis has been reported with GLP-1 receptor agonists as a class. Patients with a history of pancreatitis should discuss the risk-benefit ratio with their prescriber before starting dulaglutide.

What Is the Cheapest Way to Get Trulicity in North Carolina?

The answer depends on your insurance status. Four pathways exist, and the right one depends on your specific situation.

Commercially insured patients will pay the least by combining their insurance formulary coverage with the Eli Lilly savings card, targeting a $25, $35 monthly copay. If Trulicity is not on your plan's formulary, ask your prescriber to initiate a formulary exception request citing cardiovascular outcome data from REWIND.

Uninsured patients below 400% of the federal poverty level should apply directly to the Lilly Cares Foundation program. Processing takes 2 to 4 weeks but can result in $0 cost for 12-month renewable periods.

Medicare patients benefit from the $2,000 annual Part D out-of-pocket cap introduced in 2025. For most Medicare patients on Trulicity, total annual drug spending will not exceed $2,000 starting in 2026, a dramatic reduction from prior years when spending could exceed $5,000 annually for high-cost biologics [5].

Patients for whom brand Trulicity is financially inaccessible and who meet the clinical and regulatory criteria described in this article's compounding framework may obtain compounded dulaglutide from a licensed NC 503A pharmacy. Some NC compounding pharmacies have priced compounded dulaglutide at $150, $350 per month for cash-pay patients, though pricing is not standardized and quality varies by pharmacy.

Always confirm that a 503A pharmacy is in good standing with the NC Board of Pharmacy before using any compounded product. The Board's license lookup tool is publicly available at pharmacy.nc.gov.

How Dulaglutide's Pharmacology Drives Its Weekly Dosing

Dulaglutide is a long-acting GLP-1 receptor agonist with a plasma half-life of approximately five days. That extended half-life comes from its structure: two GLP-1 analogue sequences linked to a modified IgG4-Fc fragment via a small peptide spacer. The Fc fusion slows renal clearance and protects against peptidase degradation, maintaining therapeutic plasma concentrations across a full seven-day dosing interval [2].

Steady state is reached within two to four weeks of initiating weekly dosing. This means the first few weeks of therapy carry a lower drug exposure than the steady-state period, which partly explains why side effects often improve after the first month even without dose adjustment.

The drug is absorbed subcutaneously from the injection site (abdomen, thigh, or upper arm) and is not dependent on renal elimination for clearance, so no dose adjustment is required in mild to moderate chronic kidney disease. The REWIND trial included patients with eGFR as low as 15 mL/min/1.73m2 without a pre-specified dose reduction requirement [3].

Hepatic impairment does not meaningfully alter dulaglutide pharmacokinetics based on dedicated pharmacokinetic studies, though data in severe hepatic impairment (Child-Pugh C) are limited [2].

Titration Schedule and Starting Doses for North Carolina Patients

Trulicity is approved in four doses: 0.75 mg, 1.5 mg, 3.0 mg, and 4.5 mg, all administered once weekly. The FDA-approved titration schedule starts at 0.75 mg for four weeks, then escalates to 1.5 mg. Further escalation to 3.0 mg and then 4.5 mg can occur at four-week intervals based on glycemic response and tolerability.

The 0.75 mg dose is a starting dose only and is not expected to meet most patients' glycemic targets as a long-term maintenance dose. The 1.5 mg dose is the minimum effective maintenance dose for A1c reduction in the AWARD trials.

Starting at 0.75 mg and titrating slowly is strongly associated with better gastrointestinal tolerability. A 2022 retrospective analysis published in Diabetes Care found that patients who skipped the 0.75 mg starter phase had 2.3-fold higher rates of early discontinuation due to nausea compared to those who completed at least four weeks at the starter dose [11].

Patients in North Carolina receiving a telehealth prescription typically receive a titration schedule printed with their prescription summary and reviewed during the follow-up visit, which HealthRX schedules at the four-week mark to assess tolerability before the first dose escalation.